ENTX (Entera Bio) Short Interest


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.55
! 2 Warning Signs
View Full Analysis

What is Entera Bio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ENTX vs IMA, MNOV, ACRV: Short Interest Comparison

For the Biotechnology subindustry, Entera Bio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Short Interest distribution charts can be found below:

* The bar in red indicates where Entera Bio's Short Interest falls into.


ENTX
23GF Score
Entera Bio Ltd ENTX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price